Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan

H. H. Lin, K. L. Hsu, Wen-Chien Ko, Yi-Ching Yang, Y. W. Chang, M. C. Yu, K. T. Chen

Research output: Contribution to journalEditorial

7 Citations (Scopus)

Abstract

The aim of this study was to investigate the efficacy of the influenza vaccine among cancer patients in Taiwan. We determined the effect of immunization on the following outcomes of disease: hospitalizations, emergency department visits, hospital outpatient visits, physician office visits, and deaths. Cost-effectiveness was analysed from the perspectives of the healthcare system and society. A decision tree was used, with estimates of disease burden and costs based on data from published and unpublished sources. The model followed 34 112 cancer patients aged 20-64 years who were registered by the Taiwan National Cancer Registry in 2002. An influenza immunization programme for the cancer population would prevent 2555 cases of all types of influenza infection, 660 of which would be serious cases involving hospitalization, emergency department visits and death. From the perspective of the healthcare system, the programme would cost US$7.7 million, providing net savings of US$5.4 million. From a societal perspective, the programme would cost US$28.6 million, providing net savings of US$22.3 million. This corresponds to savings of US$2107 and US$6338 per case averted, from healthcare and societal perspectives, respectively, as well as 110 lives saved. Lesser disease burden, greater vaccine efficacy and lower cost of hospitalizations increased cost-effectiveness. Influenza immunization for cancer patients is cost-saving and cost-effective from a healthcare and societal perspective in Taiwan. We highly recommend annual influenza vaccinations for this patient group.

Original languageEnglish
Pages (from-to)663-670
Number of pages8
JournalClinical Microbiology and Infection
Volume16
Issue number6
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Taiwan
Human Influenza
Cost-Benefit Analysis
Immunization
Costs and Cost Analysis
Delivery of Health Care
Hospitalization
Neoplasms
Hospital Emergency Service
Office Visits
Physicians' Offices
Immunization Programs
Decision Trees
Cost of Illness
Influenza Vaccines
Registries
Vaccination
Outpatients
Vaccines
Infection

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Lin, H. H. ; Hsu, K. L. ; Ko, Wen-Chien ; Yang, Yi-Ching ; Chang, Y. W. ; Yu, M. C. ; Chen, K. T. / Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. In: Clinical Microbiology and Infection. 2010 ; Vol. 16, No. 6. pp. 663-670.
@article{0246cbae06a34daf9db0aff1f201184d,
title = "Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan",
abstract = "The aim of this study was to investigate the efficacy of the influenza vaccine among cancer patients in Taiwan. We determined the effect of immunization on the following outcomes of disease: hospitalizations, emergency department visits, hospital outpatient visits, physician office visits, and deaths. Cost-effectiveness was analysed from the perspectives of the healthcare system and society. A decision tree was used, with estimates of disease burden and costs based on data from published and unpublished sources. The model followed 34 112 cancer patients aged 20-64 years who were registered by the Taiwan National Cancer Registry in 2002. An influenza immunization programme for the cancer population would prevent 2555 cases of all types of influenza infection, 660 of which would be serious cases involving hospitalization, emergency department visits and death. From the perspective of the healthcare system, the programme would cost US$7.7 million, providing net savings of US$5.4 million. From a societal perspective, the programme would cost US$28.6 million, providing net savings of US$22.3 million. This corresponds to savings of US$2107 and US$6338 per case averted, from healthcare and societal perspectives, respectively, as well as 110 lives saved. Lesser disease burden, greater vaccine efficacy and lower cost of hospitalizations increased cost-effectiveness. Influenza immunization for cancer patients is cost-saving and cost-effective from a healthcare and societal perspective in Taiwan. We highly recommend annual influenza vaccinations for this patient group.",
author = "Lin, {H. H.} and Hsu, {K. L.} and Wen-Chien Ko and Yi-Ching Yang and Chang, {Y. W.} and Yu, {M. C.} and Chen, {K. T.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1469-0691.2009.02937.x",
language = "English",
volume = "16",
pages = "663--670",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "6",

}

Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. / Lin, H. H.; Hsu, K. L.; Ko, Wen-Chien; Yang, Yi-Ching; Chang, Y. W.; Yu, M. C.; Chen, K. T.

In: Clinical Microbiology and Infection, Vol. 16, No. 6, 01.01.2010, p. 663-670.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan

AU - Lin, H. H.

AU - Hsu, K. L.

AU - Ko, Wen-Chien

AU - Yang, Yi-Ching

AU - Chang, Y. W.

AU - Yu, M. C.

AU - Chen, K. T.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The aim of this study was to investigate the efficacy of the influenza vaccine among cancer patients in Taiwan. We determined the effect of immunization on the following outcomes of disease: hospitalizations, emergency department visits, hospital outpatient visits, physician office visits, and deaths. Cost-effectiveness was analysed from the perspectives of the healthcare system and society. A decision tree was used, with estimates of disease burden and costs based on data from published and unpublished sources. The model followed 34 112 cancer patients aged 20-64 years who were registered by the Taiwan National Cancer Registry in 2002. An influenza immunization programme for the cancer population would prevent 2555 cases of all types of influenza infection, 660 of which would be serious cases involving hospitalization, emergency department visits and death. From the perspective of the healthcare system, the programme would cost US$7.7 million, providing net savings of US$5.4 million. From a societal perspective, the programme would cost US$28.6 million, providing net savings of US$22.3 million. This corresponds to savings of US$2107 and US$6338 per case averted, from healthcare and societal perspectives, respectively, as well as 110 lives saved. Lesser disease burden, greater vaccine efficacy and lower cost of hospitalizations increased cost-effectiveness. Influenza immunization for cancer patients is cost-saving and cost-effective from a healthcare and societal perspective in Taiwan. We highly recommend annual influenza vaccinations for this patient group.

AB - The aim of this study was to investigate the efficacy of the influenza vaccine among cancer patients in Taiwan. We determined the effect of immunization on the following outcomes of disease: hospitalizations, emergency department visits, hospital outpatient visits, physician office visits, and deaths. Cost-effectiveness was analysed from the perspectives of the healthcare system and society. A decision tree was used, with estimates of disease burden and costs based on data from published and unpublished sources. The model followed 34 112 cancer patients aged 20-64 years who were registered by the Taiwan National Cancer Registry in 2002. An influenza immunization programme for the cancer population would prevent 2555 cases of all types of influenza infection, 660 of which would be serious cases involving hospitalization, emergency department visits and death. From the perspective of the healthcare system, the programme would cost US$7.7 million, providing net savings of US$5.4 million. From a societal perspective, the programme would cost US$28.6 million, providing net savings of US$22.3 million. This corresponds to savings of US$2107 and US$6338 per case averted, from healthcare and societal perspectives, respectively, as well as 110 lives saved. Lesser disease burden, greater vaccine efficacy and lower cost of hospitalizations increased cost-effectiveness. Influenza immunization for cancer patients is cost-saving and cost-effective from a healthcare and societal perspective in Taiwan. We highly recommend annual influenza vaccinations for this patient group.

UR - http://www.scopus.com/inward/record.url?scp=77953954347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953954347&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2009.02937.x

DO - 10.1111/j.1469-0691.2009.02937.x

M3 - Editorial

C2 - 19709066

AN - SCOPUS:77953954347

VL - 16

SP - 663

EP - 670

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 6

ER -